Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP) -- Ignore unavailable to you. Want to Upgrade?

To: Harold Lehman who wrote (789)	1/21/1998 5:40:00 PM
From: Harold Engstrom	Read Replies (1) \| Respond to of 1501

I'm not sure what methods of delivery Merck plans to use, but I didn't see anything written anywhere that they were limiting themselves to inhalation. The charts on display at the annual meeting seemed to show virtually no response relative to the untreated charts: I think Biogen's investor relations department would have no problem in showing anyone copies of the powerpoint presentation. But, personally I can't quantify the results of the sheep modelling. From what I remember I would feel very comfortable with 90%+.